Replies to post #11336 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Clinical, Preclinical Goals for 2008-2009
(From Collins Stewart webcast, 9-Jul-2008)



The entry for HR (heparin resistance) protocol review is new.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”